《抗击新冠肺炎疫情的中国行动》白皮书（双语全文）(79)

实施科研应急攻关。遵循安全、有效、可供的原则，加快推进药物、疫苗、新型检测试剂等研发和应用。适应疫情防控一线的紧迫需求，围绕“可溯、可诊、可治、可防、可控”，坚持产学研用相结合，聚焦临床救治和药物、疫苗研发、检测技术和产品、病毒病原学和流行病学、动物模型构建5大主攻方向，组织全国优势力量开展疫情防控科技攻关，加速推进科技研发和应用，部署启动83个应急攻关项目。按照灭活疫苗、重组蛋白疫苗、减毒流感病毒载体疫苗、腺病毒载体疫苗、核酸疫苗等5条技术路线开展疫苗研发。目前，已有4种灭活疫苗和1种腺病毒载体疫苗获批开展临床试验，总体研发进度与国外持平，部分技术路线进展处于国际领先。组织科研团队开展科学溯源研究。Key progress has been made in scientific research.Following the principles of safety, effectiveness and availability, China has accelerated the R&D and application of medicines, vaccines, and new test kits. To meet the urgent needs of frontline virus control, and to ensure traceability of infection sources, diagnosis and treatment of patients, and prevention and control of infections, China has pooled resources from enterprises, universities, and research institutes, directing them to focus on five areas – clinical treatment, new medicines and vaccines, testing techniques and products, viral etiology and epidemiology, and animal model construction. Top research resources from around the nation have been galvanized to work on these tasks in pursuit of early results and application. A total of 83 emergency R&D programs have been initiated. Vaccines are being developed in five categories – inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines, and nucleic acid-based vaccines. To date, four inactivated vaccines and one adenovirus vaccine have been approved for clinical trials. While scientists in China and abroad have kept up with mutual developments, China leads the world in the development of certain types of vaccines. Research teams have also been assembled to trace the origin of Covid-19.